Is It Time to Change the Independent Dispute Resolution Process of the No Surprises Act? Read More February 1, 2026
Premise-Crossover Merger: Inside the $2B Push for a New Employer Health Model Read More February 1, 2026
Clinical Trial Holds Cast Doubt on Approval Chances of Regenxbio Gene Therapy for Rare Disease Read More February 1, 2026
AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds Read More January 30, 2026